Concepedia

Author

C. Mircea S. Tesileanu

Sorbonne UniversitéORCID

Also Known As

C M S Tesileanu, C Mircea S Tesileanu, C. Mircea S. Tesileanu, C. Mircea S. Tesileanu

62

Publications

849

Citations

11

H-Index

17

Concepts

All Affiliations

Sorbonne UniversitéMoffitt Cancer CenterIstituto delle Scienze Neurologiche di BolognaErasmus MC Cancer InstituteEuropean Organisation for Research and Treatment of Cancer
CM

About

C. Mircea S. Tesileanu is an author at Sorbonne Université specializing in cancer therapeutics, medicine, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

2

2

336

2

Medicine

2

2

336

3

Pathology

1

1

29

4

Pharmacology

1

1

29

5

Surgical Oncology

1

1

307

C. Mircea S. Tesileanu

×

9

Publications

780

Citations

9

H-Index

YearCitations

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

Martin J. van den Bent, C. Mircea S. Tesileanu, Wolfgang Wick,

The Lancet Oncology

2021

307

Survival of diffuse astrocytic glioma, IDH1/2 wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria

C. Mircea S. Tesileanu, Linda Dirven, Maarten M.J. Wijnenga,

Neuro-Oncology

2019

207

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i> -wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial

C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick,

Clinical Cancer Research

2022

68

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

C. Mircea S. Tesileanu, Martin J. van den Bent, Marc Sanson,

Neuro-Oncology

2021

59

Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations

C. Mircea S. Tesileanu, Wies Vallentgoed, Marc Sanson,

Acta Neuropathologica

2021

52

PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion

Martin J. van den Bent, Sara Erridge, Michael A. Vogelbaum,

Neuro-Oncology

2019

29

<i>IDH1/2</i>wildtype gliomas grade 2 and 3 with molecular glioblastoma-like profile have a distinct course of epilepsy compared to<i>IDH1/2</i>wildtype glioblastomas

Mark P. van Opijnen, C. Mircea S. Tesileanu, Linda Dirven,

Neuro-Oncology

2022

22

Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033

Johan M. Kros, Elisabeth J. Rushing, Aimé Lambert Uwimana,

Neuro-Oncology

2022

22

Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma

Santoesha A. Ghisai, Levi van Hijfte, Wies Vallentgoed,

Acta Neuropathologica

2024

14

Page 1